Intramyocardial Implantation of CD133 + Stem Cells Improved Cardiac Function without Bypass Surgery

Klein, Hans-Martin; Ghodsizad, Ali; Marktanner, Ralph; Poll, L. W.; Voelkel, Tobias; Hasani, Motahareh; Piechaczek, Christoph; Feifel, N.; Stockschlaeder, Marcus; Burchardt, Elmar R.; Kar, B.; Gregorič, Igor D.; Gams, E.

doi:10.1532/hsf98.20061054

Cited by 86 publications

(50 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The preliminary results presented here are in agreement with previous studies in which stem cells were delivered via transepicardial [6,15,16] or transendocardial [2,3,5] routes. The uncomplicated postoperative period of this patient suggests that the procedure is safe.…”

Section: Discussionsupporting

confidence: 92%

“…Several reports suggest the use of selected bone marrow-derived stem cells that have higher angiogenic capacities [13][14][15][16][17]. AC133 + and CD34 + stem cells are the most frequently used type of stem cells in these studies.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies report the use of minimally invasive techniques for the injection of stem cells into myocardium [15][16]. Because we wanted to perform coronary bypass grafting to the target vessel, we planned on using median sternotomy.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Neoangiogenesis after direct intramyocardial implantation of bone marrow-derived stem cells in a patient with severe coronary artery disease ineligible for percutaneous or surgical revascularization

et al. 2009

View full text Add to dashboard Cite

AbstractBone marrow-derived stem cells (BMSC) may be an alternative for the treatment of patients with severe coronary artery disease ineligible for either percutaneous or surgical revascularization. This case report presents a 65-year-old male patient with untreatable angina pectoris (Canadian Cardiovascular Society Class III) and severe coronary artery disease. A mixture of BMSC containing approximately 3×106 CD34+ cells was directly injected into preoperatively determined ischemic regions of the myocardium by median sternotomy. At baseline, at 3 months, and at 1 year of follow-up, echocardiography (demonstrating wall motions of 16 segments), single-photon emission computed tomography, and coronary angiography (at baseline and at 1 year) were performed to assess myocardial perfusion, left ventricular (LV) function and coronary anatomy. The patient reached Canadian Cardiovascular Society Class I after 6 months of cell implantation. The ejection fraction increased from 34% to 37% at the third month and 40% at 1 year of follow-up. At 1 year of follow-up, preoperatively akinetic mid-base septum and anteroseptal regions progressed to mild hipokinesia and severe hypokinetic mid-base-apical anterior regions and apical lateral-inferior regions became normokinesia. Single-photon emission computed tomography revealed a visible improvement in anterior and lateral segments at 1 year of follow-up. Coronary angiography showed newly developed collateral arteries at 1 year of follow-up. BMSC transplantation in a patient with severe coronary artery disease resulted in increase of LV ejection fraction, an increase of the perfusion of ischemic myocardial regions, and improvement in wall motion defects without any adverse events.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neoangiogenesis after direct intramyocardial implantation of bone marrow-derived stem cells in a patient with severe coronary artery disease ineligible for percutaneous or surgical revascularization

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Particularly autologous CD34 ϩ or CD133 ϩ stem/ progenitor cells have been therapeutically transplanted in patients with severe ischemic heart or limb diseases, and these initial clinical experiences indicate the safety and feasibility as well as the effectiveness of cell-based therapy [3,[11][12][13][14][15][16][17][18][19].…”

Section: Several Translational Researchers Have Demonstrated That Cd34mentioning

confidence: 99%

Development of Serum-Free Quality and Quantity Control Culture of Colony-Forming Endothelial Progenitor Cell for Vasculogenesis

Masuda

Iwasaki

Kawamoto

et al. 2012

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Quantitative and qualitative impairment of endothelial progenitor cells (EPCs) limits the efficacy of autologous cell therapy in patients with cardiovascular diseases. Here, we developed a serum-free quality and quantity control culture system for colony-forming EPCs to enhance their regenerative potential. A culture with serum-free medium containing stem cell factor, thrombopoietin, vascular endothelial growth factor, interleukin-6, and Flt-3 ligand was determined as optimal quality and quantity culture ( MEDICINE 2012;1:160 -171

show abstract

“…Transepicardial application is performed during CABG procedure, which allows direct access to the ischaemic border-zone (Patel et al, 2005;Stamm et al, 2007). In addition, transepicardial injection can be performed through microthoracotomy (Klein et al, 2007;Pompilio et al, 2008).…”

Section: Figurementioning

confidence: 99%

Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology

Jadczyk

Faulkner

Madeddu

2013

British J Pharmacology

View full text Add to dashboard Cite

Regenerative medicine holds great promise as a way of addressing the limitations of current treatments of ischaemic disease. In preclinical models, transplantation of different types of stem cells or progenitor cells results in improved recovery from ischaemia. Furthermore, experimental studies indicate that cell therapy influences a spectrum of processes, including neovascularization and cardiomyogenesis as well as inflammation, apoptosis and interstitial fibrosis. Thus, distinct strategies might be required for specific regenerative needs. Nonetheless, clinical studies have so far investigated a relatively small number of options, focusing mainly on the use of bone marrow-derived cells. Rapid clinical translation resulted in a number of small clinical trials that do not have sufficient power to address the therapeutic potential of the new approach. Moreover, full exploitation has been hindered so far by the absence of a solid theoretical framework and inadequate development plans. This article reviews the current knowledge on cell therapy and proposes a model theory for interpretation of experimental and clinical outcomes from a pharmacological perspective. Eventually, with an increased association between cell therapy and traditional pharmacotherapy, we will soon need to adopt a unified theory for understanding how the two practices additively interact for a patient's benefit. LINKED ARTICLESThis article is part of a themed section on Regenerative Medicine and Pharmacology: A Look to the Future. To view the other articles in this section visit http://dx

show abstract

Intramyocardial Implantation of CD133 + Stem Cells Improved Cardiac Function without Bypass Surgery

Cited by 86 publications

References 17 publications

Neoangiogenesis after direct intramyocardial implantation of bone marrow-derived stem cells in a patient with severe coronary artery disease ineligible for percutaneous or surgical revascularization

Neoangiogenesis after direct intramyocardial implantation of bone marrow-derived stem cells in a patient with severe coronary artery disease ineligible for percutaneous or surgical revascularization

Development of Serum-Free Quality and Quantity Control Culture of Colony-Forming Endothelial Progenitor Cell for Vasculogenesis

Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology

Contact Info

Product

Resources

About